Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD)

被引：1
|
作者：
Yoroidaka, Takeshi [1 ,2 ]
Takamatsu, Hiroyuki [1 ]
Yamashita, Takeshi [3 ]
Murata, Ryoichi [3 ]
Yoshihara, Kyoko [4 ]
Yoshihara, Satoshi [4 ]
Ueda, Mikio [3 ]
Nakao, Shinji [1 ]
Matsue, Kosei [5 ]
机构：
[1] Kanazawa Univ, Dept Hematol, Kanazawa, Ishikawa, Japan
[2] Keiju Med Ctr, Dept Internal Med, Nanao, Japan
[3] Keiju Kanazawa Hosp, Dept Internal Med, Kanazawa, Ishikawa, Japan
[4] Hyogo Coll Med, Dept Hematol, Nishinomiya, Hyogo, Japan
[5] Kameda Med Ctr, Div Hematol Oncol, Dept Med, Kamogawa, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126552
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3130
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
    Piedra, Katrina
    Peterson, Tim
    Tan, Carlyn
    Orozco, Jennifer
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Lesokhin, Alexander
    Shah, Urvi
    Lu, Sydney
    Patel, Dhwani
    Derkach, Andriy
    Wilkins, Cy R.
    Korde, Neha
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 105 - 109
  • [32] CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Ri, M.
    Suzuki, K.
    Chou, T.
    Sugiura, I.
    Takezako, N.
    Sunami, K.
    Ishida, T.
    Izumi, T.
    Ozaki, S.
    Iida, S.
    HAEMATOLOGICA, 2016, 101 : 787 - 788
  • [33] ECONOMIC EVALUATION OF CARFILZOMIB plus LENALIDOMIDE plus DEXAMETHASONE (KRD) VS LENALIDOMIDE plus DEXAMETHASONE (RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (R/RMM)
    Fonseca, R.
    Panjabi, S.
    Campioni, M.
    Giannopoulou, A.
    Benedict, A.
    Houisse, I.
    Aggarwal, S.
    Jakubowiak, A.
    HAEMATOLOGICA, 2016, 101 : 526 - 526
  • [34] Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
    Bhutani, Manisha
    Robinson, Myra
    Atrash, Shebli
    Watts, Nicole
    Paul, Barry
    Chhabra, Saurabh
    Korde, Neha
    Begic, Xhevahire
    Foureau, David M.
    Chung, David J.
    Pineda-Roman, Mauricio
    Koya, Brinda
    Varga, Cindy
    Ai, Jing
    Daniels, Natonya
    Norek, Sarah
    Sutton, Sara A.
    Anderson, Michelle B.
    Jewell, Ashley N.
    Eldridge, Paul W.
    Acampora, Donna
    Symanowski, James T.
    Costa, Luciano J.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 4393 - 4395
  • [35] Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)
    van Vliet, Martin
    Jasielec, Jagoda
    Dytfeld, Dominik
    Vij, Ravi
    Dumee, Belinda
    Bosman, Lizanne
    deBest, Leonie C. M.
    Alonge, Mattina
    Rosebeck, Shaun
    Kandarpa, Malathi
    McDonnell, Kathryn
    Griffith, Kent A.
    van Beers, Erik H.
    Jakubowiak, Andrzej
    BLOOD, 2014, 124 (21)
  • [36] Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients
    Morabito, Fortunato
    Zamagni, Elena
    Conticello, Concetta
    Pavone, Vincenzo
    Palmieri, Salvatore
    Bringhen, Sara
    Galli, Monica
    Mangiacavalli, Silvia
    Derudas, Daniele
    Rossi, Elena
    Ria, Roberto
    Catalano, Lucio
    Tacchetti, Paola
    Mele, Giuseppe
    Vincelli, Iolanda Donatella
    Martino, Enrica Antonia
    Vigna, Ernesto
    Botta, Cirino
    Bruzzese, Antonella
    Mele, Anna
    Pantani, Lucia
    Rocchi, Serena
    Garibaldi, Bruno
    Cascavilla, Nicola
    Ballanti, Stelvio
    Tripepi, Giovanni
    Frigeri, Ferdinando
    Falcone, Antonetta Pia
    Cangialosi, Clotilde
    Reddiconto, Giovanni
    Farina, Giuliana
    Barone, Marialucia
    Rizzello, Ilaria
    Musto, Pellegrino
    De Stefano, Valerio
    Musso, Maurizio
    Petrucci, Maria Teresa
    Offidani, Massimo
    Neri, Antonino
    Di Renzo, Nicola
    Di Raimondo, Francesco
    Boccadoro, Mario
    Cavo, Michele
    Gentile, Massimo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 108 (03) : 178 - 189
  • [37] Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd)
    Maura, Francesco
    Boyle, Eileen M.
    Diamond, Benjamin
    Blaney, Patrick
    Ghamlouch, Hussein
    Ziccheddu, Bachisio
    Wang, Yubao
    Maclachlan, Kylee H.
    Hoffman, James E.
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Tan, Carlyn
    Hultcrantz, Malin
    Scordo, Michael
    Kazandjian, Dickran
    Shah, Gunjan L.
    Landau, Heather J.
    Chung, David J.
    Giralt, Sergio
    Bruno, Benedetto
    Zhang, Yanming
    Arbini, Arnaldo A.
    Dogan, Ahmet
    Lesokhin, Alexander
    Davies, Faith E.
    Korde, Neha
    Morgan, Gareth J.
    Landgren, Ola
    BLOOD, 2021, 138
  • [38] CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA PATIENTS: SUBGROUP ANALYSIS IN THE FORTE TRIAL
    Gay, F.
    Cerrato, C.
    Petrucci, M. T.
    Zambello, R.
    Rivolti, E.
    Ballanti, S.
    Omede, P.
    Gentile, M.
    Bernardini, A.
    Narni, F.
    Capra, A.
    De Sabbata, G.
    Gozzetti, A.
    Galieni, P.
    Rizzi, R.
    Pescosta, N.
    Cea, M.
    Molica, S.
    Cafro, A.
    Musolino, C.
    Spadano, A.
    Montefusco, V.
    Musto, P.
    Cavo, M.
    Boccadoro, M.
    HAEMATOLOGICA, 2019, 104 : 2 - 3
  • [39] KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
    Salvatore Palmieri
    S. Rocco
    O. Vitagliano
    L. Catalano
    C. Cerchione
    I. D. Vincelli
    A. Scopelliti
    M. Gentile
    G. Farina
    M. Barone
    A. Gagliardi
    D. Esposito
    M. Arcamone
    V. Amico
    R. Fontana
    A. Sementa
    A. Sica
    G. Svanera
    F. Pane
    F. Ferrara
    Annals of Hematology, 2020, 99 : 2903 - 2909
  • [40] KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
    Palmieri, Salvatore
    Rocco, S.
    Vitagliano, O.
    Catalano, L.
    Cerchione, C.
    Vincelli, I. D.
    Scopelliti, A.
    Gentile, M.
    Farina, G.
    Barone, M.
    Gagliardi, A.
    Esposite, D.
    Arcamone, M.
    Amico, V
    Fontana, R.
    Sementa, A.
    Sica, A.
    Svanera, G.
    Pane, F.
    Ferrara, F.
    ANNALS OF HEMATOLOGY, 2020, 99 (12) : 2903 - 2909
12345